Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:10:44 ON 25 SEP 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 21:10:58 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10825611.str





chain nodes :
17 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
6-12 9-17 13-19 14-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 10-11 10-14 11-12
12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 6-12 7-8 8-9 9-17 10-11 10-14
11-12 12-13 13-14 13-19 14-20
isolated ring systems :
containing 1 : 10 :

G1:N,CH

G2:H,Ak

G3:H,X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 17:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 21:11:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 45 TO ITERATE

100.0% PROCESSED 45 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 498 TO 1302
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 21:11:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 905 TO ITERATE

100.0% PROCESSED 905 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L3 10 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 21:11:35 ON 25 SEP 2006

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d l4 ibib hitstr abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:380892 CAPLUS
DOCUMENT NUMBER: 144:432795
TITLE: Preparation of pyrazole derivatives as selective phosphodiesterase 4 inhibitors
INVENTOR(S): Hopper, Allen; Dunn, Robert F.; Kuester, Erik Mikal; Conticello, Richard D.
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044528	A1	20060427	WO 2005-US36801	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006154960	A1	20060713	US 2005-249769	20051014
PRIORITY APPLN. INFO.:			US 2004-618725P	P 20041015

OTHER SOURCE(S): MARPAT 144:432795
IT 784189-89-5P 885131-71-5P 885131-78-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing
cognition and treating psychosis, allergic conditions, or inflammatory
disease)
RN 784189-89-5 CAPLUS
CN 1H-Indazole,
1-cyclopentyl-6-[1-[(2,3-difluorophenyl)methyl]-1H-pyrazol-3-yl]-3-ethyl- (9CI) (CA INDEX NAME)



RN 885131-71-5 CAPLUS
CN 1H-Indazole, 1-cyclopropyl-3-ethyl-6-(1H-pyrazol-3-yl)- (9CI) (CA INDEX
NAME)



RN 885131-78-2 CAPLUS
CN 1H-Indazole, 1-cyclopropyl-3-ethyl-6-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 784189-88-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing
cognition and treating psychosis, allergic conditions, or inflammatory
disease)
RN 784189-88-4 CAPLUS
CN 1H-Indazole, 1-cyclopentyl-3-ethyl-6-(1H-pyrazol-3-yl)- (9CI) (CA INDEX
NAME)



GI



I



II

AB Title (hetero)aryl pyrazole compds. I [wherein Ar = substituted Ph,

pyridinyl, benzo-furanyl, benzo-pyrazolyl, pyrazolo[4,3-b]pyridinyl; L =
bond, (CH2)nCONH, (CH2)nCON(alkyl), (CH2)nNHCO, (CH2)nCONHSO2, (CH2)nSO2NH, (CH2)nSO2, (CH2)nCO2, (un)substituted alkylene optionally interrupted by O, NH, S; n = 0-3; R3 = H, (un)substituted (cyclo)alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R7, R8 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl; and pharmaceutically acceptable salts thereof] were prepared The invention compds. exhibited improved phosphodiesterase 4 (PDE4) inhibition as compared to compds. such as rolipram and showed selectivity with regard to inhibition of other classes of PDEs. For example, 3-hydroxy-4-methoxy-benzaldehyde was condensed with (S)-3-hydroxy-tetrahydrofuran using PPh3 and DIAD in THF to give (R)-4-methoxy-3-[(tetrahydrofuran-3-yl)oxy]benzaldehyde (66%). Reaction of the aldehyde with diethoxyphosphorylacetaldehyde tosyl-hydrazone in the presence of NaH in THF provided the desired pyrazole II (57%). Compds. of the invention blocked the human PDE4 mediated conversion of cAMP to adenosine with IC50 values ranging from 10 nM to 5000 nM. Thus, I and their pharmaceutical compns. are useful for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, head trauma or age-related cognitive decline, schizophrenia, bipolar or manic depression, major depression, drug addiction or morphine dependence (no data).

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:927199 CAPLUS
DOCUMENT NUMBER: 141:379922
TITLE: Preparation of pyrazole derivatives as selective phosphodiesterase 4 inhibitors
INVENTOR(S): Hopper, Allen; Kuester, Erik; Dunn, Robert; Conticello, Richard
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004094411	A1	20041104	WO 2004-US11899 20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004232973	A1	20041104	AU 2004-232973 20040416
CA 2522687	AA	20041104	CA 2004-2522687 20040416
US 2004229918	A1	20041118	US 2004-825611 20040416
EP 1631568	A1	20060308	EP 2004-759965 20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009888	A	20060523	BR 2004-9888 20040416
CN 1809559	A	20060726	CN 2004-80017033 20040416
PRIORITY APPLN. INFO.:			US 2003-463725P P 20030418
			WO 2004-US11899 W 20040416

OTHER SOURCE(S): MARPAT 141:379922

IT 784189-88-4P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1H-pyrazole
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE4 inhibitor; preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

RN 784189-88-4 CAPLUS

CN 1H-Indazole, 1-cyclopentyl-3-ethyl-6-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT 784189-89-5P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(2,3-difluorobenzyl)-1H-pyrazole 784190-55-2P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(4-carboxyphenyl)-1H-pyrazole 784190-57-4P,

3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(4-methoxyphenyl)-1H-pyrazole 784190-58-5P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(2-methylbenzyl)-1H-pyrazole 784190-59-6P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(4-methylsulfonylbenzyl)-1H-pyrazole 784190-60-9P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-[(2-pyridyl)methyl]-1H-pyrazole 784191-48-6P, 3-(1-Cyclopentyl-3-ethylindazol-6-yl)-1-(2,3-difluorophenyl)pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 inhibitor; preparation of pyrazole derivs. as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

RN 784189-89-5 CAPLUS
CN 1H-Indazole, 1-cyclopentyl-6-[1-[(2,3-difluorophenyl)methyl]-1H-pyrazol-3-yl]-3-ethyl- (9CI) (CA INDEX NAME)



RN 784190-55-2 CAPLUS
CN Benzoic acid, 4-[3-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 784190-57-4 CAPLUS
CN 1H-Indazole, 1-cyclopentyl-3-ethyl-6-[1-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 784190-58-5 CAPLUS
CN 1H-Indazole, 1-cyclopentyl-3-ethyl-6-[1-[(2-methylphenyl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 784190-59-6 CAPLUS
CN 1H-Indazole,
1-cyclopentyl-3-ethyl-6-[1-[[4-(methylsulfonyl)phenyl]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 784190-60-9 CAPLUS
CN 1H-Indazole,
1-cyclopentyl-3-ethyl-6-[1-(2-pyridinylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 784191-48-6 CAPLUS
CN 1H-Indazole,
1-cyclopentyl-6-[1-(2,3-difluorophenyl)-1H-pyrazol-3-yl]-3-ethyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Title (hetero)aryl pyrazole compds. I [wherein Ar = substituted Ph, pyridinyl, benzofuranyl, benzopyrazolyl, pyrazolo[4,3-b]pyridinyl; L = bond, (CH2)nCONH, (CH2)nCON(alkyl), (CH2)nNHCO, (CH2)nCONHSO2, (CH2)nSO2NH, (CH2)nSO2, (CH2)nCO2, (un)substituted alkylene optionally interrupted by O, NH, S; n = 0-3; R3 = H, (un)substituted (cyclo)alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R7, R8 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl; and pharmaceutically acceptable

salts thereof] were prepared The invention compds. exhibited improved phosphodiesterase 4 (PDE4) inhibition as compared to compds. such as rolipram and showed selectivity with regard to inhibition of other classes of PDEs. For example, 3-hydroxy-4-methoxybenzaldehyde was condensed with (S)-3-hydroxytetrahydrofuran using PPh3 and DIAD in THF to give (R)-4-methoxy-3-[(tetrahydrofuran-3-yl)oxy]benzaldehyde (66%). Reaction of the aldehyde with diethoxyphosphorylacetaldehyde tosylhydrazone in the presence of NaH in THF provided the desired pyrazole II (57%). Compds. of the invention blocked the human PDE4 mediated conversion of cAMP to adenosine with IC50 values ranging from 10 nM to 5000 nM. Thus, I and their pharmaceutical compns. are useful for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease (no data).

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.68	177.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

STN INTERNATIONAL LOGOFF AT 21:11:58 ON 25 SEP 2006